Faruqi and Faruqui, LLP Logo
Share this page

Obalon Therapeutics, Inc. (OBLN)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Obalon Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN).

On January 23, 2018, Obalon announced that it would terminate its previously announced public offering of 5,454,545 shares of common stock at $5.50 per share, scheduled for the same day. The termination of the offering occurred after the Company was informed, on January 22, 2018, that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.”

On this news, Obalon’s share price fell from $5.19 per share on January 22, 2018 to a closing price of $3.46 on January 23, 2018—a $1.73 or a 33.3% drop.

If you invested in Obalon stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Obalon Therapeutics, Inc. (OBLN)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 01/24/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.